Biogen to Present New Data at Upcoming ECTRIMS 2015 Congress on MS Therapies, Including TECFIDERA

Biogen to Present New Data at Upcoming ECTRIMS 2015 Congress on MS Therapies, Including TECFIDERA

Biogen, a biotechnology company focused on innovative therapies for autoimmune disorders, neurodegenerative diseases and hematological conditions, recently announced that it will present new data on its multiple sclerosis (MS) portfolio of therapeutic agents at the upcoming 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) to be held in Barcelona, Spain, on October 7-10, 2015.

TECFIDERA (dimethyl fumarate) is the most prescribed oral MS treatment from Biogen. Researchers will present new clinical data showing the robust and sustained efficacy of TECFIDERA on key measures of disease activity in patients with relapsing forms of MS, who were newly diagnosed or were in a an early stage of disease course. TECFIDERA has been previously reported to reduce the relapse rates, slow disability progression and the number of brain lesions in MS patients.

“TECFIDERA’s compelling combination of benefits has made it the most-prescribed oral MS medication globally. At ECTRIMS, Biogen will present data that underscore the benefits of early treatment of RRMS with TECFIDERA and reaffirm its favorable benefit-risk profile in a broad range of patients,” said the vice president of Multiple Sclerosis Research and Development at Biogen, Dr. Gilmore O’Neill in a press release.

Studies have suggested that the delay in MS treatment can increase the risk of disease progression in comparison to treatment early in the disease course with an effective disease modifying therapy (DMT), such as TECFIDERA. In chronic disorders like MS, an early treatment can help slow down disease activity.

Apart from TECFIDERA, Biogen will also present results from other investigational MS therapies from the company, namely data on a Phase 3 trial on ZINBRYTATM (daclizumab high-yield process) and Phase 2 trial results on anti-LINGO-1 (BIIB033) for acute optic neuritis (inflammation of the optic nerve as a consequence of MS). New data on the efficacy of TYSABRI (natalizumab) and PLEGRIDY (peginterferon beta-1a) will also be presented.

Biogen will also present work on initiatives and collaborations established focused on approaches to improve MS management and individualized treatment outcomes.

For a complete list of Biogen’s scheduled presentations at ECTRIMS 2015 please follow the link.

Multiple Sclerosis News Today, part of the BioNews Services group, will attend the ECTRIMS 2015 Congress and offer readers real-time data and updates as they are disclosed at the meeting.


    • Michael Nace says:

      Hi Cristian. Yes, we will have a correspondent at ECTRIMS and will be live blogging and streaming in photos, video and other media direct from the conference.

  1. spiro says:

    I will be curious to see what the phase II anti-LINGO data will show. The phase I trial was a mixed bag: while the drug increased the rate of electrical transmission in affected nerve fibers, its effect on clinical changes, such as visual improvement parameters, was not significant. This will be one of the earliest reports that might answer the question whether or not remyelination will help MS patients, whether RRMS or progressive.

Leave a Comment

Your email address will not be published. Required fields are marked *